AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00902317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoplasty (PolarCath peripheral balloon catheter)
Description: Cryoplasty involves advancing the balloon catheter to the site of the lesion and delivering liquid nitrous oxide into the balloon, where it expands into gas and inflates the balloon.
Study NCT00902317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Angioplasty (Spectranetics)
Description: The basic concept of laser angioplasty is to apply light energy directly to the arterial plaque, thereby altering the plaque in some helpful way, without damaging the surrounding artery.
Study NCT00902317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SilverHawk Atherectomy
Description: Once the catheter is connected to the cutter driver, by retracting the positioning lever this simultaneously turns on the motor and caused the distal portion of the cutter housing to deflect, forcing the device against the target lesion.
Study NCT00902317 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viabahn Endograft
Description: The Gore-Viabahn should be positioned across the target lesion using the radiopaque hub and tip markers on the catheter. These markers identify the proximal and distal ends of the device, respectively.
Study NCT00902317 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Angioplasty/Stent (Guidant Absolute stent)
Description: A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface.
Study NCT01802450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study NCT04504305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NeuropAWAY
Description: 2 capsules thrice daily to be taken half an hour prior to meal.
Study NCT04504305 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcystalline cellulose
Description: 2 capsules thrice daily to be taken half an hour prior to meal.
Study NCT00790335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Description: Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
Study NCT00933348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPAL A
Description: OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.
Study NCT00933348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
Study NCT01342900 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: connected to the InSpectra Monitor
Study NCT03850925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy
Description: 4 consecutive sessions of laser therapy
Study NCT03850925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: 4 consecutive sessions of laser therapy
Study NCT03509805 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: polysomnography
Study NCT02213510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zip Surgical Skin Closure Device
Description: The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
Study NCT02213510 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Suture Closure
Description: The surgeon will perform standard suture closure for the skin layer following CIED procedure.
Study NCT02935621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Description: Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
Study NCT02935621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group
Description: A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
Study NCT00554190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AdvaCoat sinus gel
Description: A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body
Study NCT00554190 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Merogel Injectable
Description: Bioresorbable hyaluronic acid product
Study NCT02902367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outdoor walking and strength exercise
Description: Exercise group: Participants are supposed to perform an outdoor walking exercise program and one strength exercise for 12 weeks. The first 2 weeks start with daily walks. The intensity and frequency of walks will progressively increase performed according to the Borg scale: 12-15, ie, moderate to strenuous. Participants will walk 5-7 days/week. Added to this is a strength exercise, i.e. chair-rising which also should be performed daily.
Study NCT02902367 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Control-Group: Treatment as usual for 12 weeks, without restriction of being physically active.
Study NCT01177475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples , feces samples
Description: After the 32nd week until the 36th week or the end of hospitalization,infants received mother's native milk or substitute.
Study NCT01177475 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood samples, feces samples
Description: After the 32nd week until the 36th week or the end of hospitalization,infants continued mother's native milk or received substitute.
Study NCT02359994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerClot Polysaccharide Hemostatic System
Description: During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot. The prescribed hemostatic agent will be applied according to its Instructions for Use.
Study NCT02359994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arista AH
Description: During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
Study NCT04639804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegoprazan
Description: Tegoprazan 50 mg tablet
Study NCT04639804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500 mg tablet
Study NCT04639804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aceclofenac
Description: Aceclofenac 100 mg tablet
Study NCT04639804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200 mg capsule
Study NCT04562155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Study drug BAY1817080 will be administered orally as tablet.
Study NCT04562155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo for BAY1817080 will be administered orally as tablet.
Study NCT03893097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: 40 mg/kg at baseline
Study NCT03893097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate + Mefloquine
Description: 4mg/kg artesunate and 8 mg/kg mefloquine at baseline (3 consecutive days) and repeated at Week 6 and Week 12
Study NCT00537420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Placebo
Description: Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
Study NCT00537420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo capsules will be taken once daily with or without food.
Study NCT00537420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYY3-36
Description: Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
Study NCT00537420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYY3-36
Description: Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
Study NCT00537420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sibutramine
Description: Sibutramine will be taken once daily with or without food
Study NCT00999427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Description: Povidone-iodine 10% solution. A piece of 10x10 cm gauze soaked in Povidone-iodine 10% solution wrapped around the index finger of the examiner is inserted into the rectum of the subject in arm A. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin of the prostate gland to the other. The examiner will allow at least 2 minutes to elapse between antisepsis and the insertion of the first needle into the prostate in order to allow the Povidone-iodine to dry.
Study NCT06231056 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic iNatal®
Description: iNatal® (Enterococcus faecium L3, Bifidobacterium animalis subsp. lactis BB-12, Lactococcus lactis SP38, Lacticaseibacillus casei R0215)
Study NCT00421395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90Y-hLL2
Description: weekly dosing for either 2 or 3 weeks
Study NCT02325570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP)
Description: Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
Study NCT02325570 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scaling and Root Planing (SRP)
Description: Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
Study NCT02441907 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: aflibercept
Study NCT03978741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yōni.Fit Test Device
Description: The Yōni.Fit Test Device is a silicone pessary.
Study NCT03978741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Yōni.Fit Comparator Device
Description: The Yōni.Fit Comparator Device is a silicone pessary with a different configuration.
Study NCT00832598 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]FACBC PET and [18F]FLT PET imaging
Description: \[18F\]FACBC PET and \[18F\]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
Study NCT02531360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-815 (MNI-815)
Description: All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
Study NCT03129698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Apatinib 250mg daily
Study NCT04412369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive cardiac imaging
Description: Cardiac MRI ± CT coronary angiography ± Cardiac PET/MRI (68Ga-DOTATATE or 18F-FDG)
Study NCT00056316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Education
Description: Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
Study NCT02787005 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study NCT01804933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: profound neuromuscular blockade
Description: Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively
Study NCT01231971 — intervention group
Intervention type: DRUG
Intervention: Florbetapir
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
Study NCT01231971 — intervention group
Intervention type: DRUG
Intervention: Flortaucipir
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Study NCT00833612 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Counterpulsation with IAB
Description: IABC pre-reperfusion PCI
Study NCT01804933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: profound neuromuscular blockade
Description: Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively
Study NCT01731340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Citrate
Description: 750mg
Study NCT01731340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Dietary Calcium
Description: 450 mg
Study NCT04116372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Online Platform
Description: The website has 10 lessons that the participant will gain access to on a weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity
Study NCT01379482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal treatment
Description: 3 months (range 2-4.5) with neoadjuvant systemic chemotherapy. Four weeks after receiving the last course of chemotherapy, patients will undergo laparotomy with the objective of performing cytoreduction + hyperthermic intraperitoneal chemotherapy.~Early peritoneal chemotherapy though intrabdominal drains for the first five postoperative days.~Neo-adjuvant chemotherapy:~Irinotecan+Nordic FLv (6 pat.) EOX (6 pat.) FLOX (3 pat.) Docetaxel+Irinotecan+5-FU+LV (1 pat.) FOLFIRI (1 pat.) ECF (1 pat.)~Hyperthermic intraoperative chemotherapy:~Cisplatin+doxorubicin (5 pat.). Oxaliplatin +concomitant i.v. 5-FU+ i.v. LV (3 pat.)~Early postoperative chemotherapy:~5-FU + i.v. LV (5 pat.) Paclitaxel (1 pat.)
Study NCT03387189 — intervention group
Intervention type: OTHER
Intervention: Quality Improvement Project
Description: Simulation education conducted at Regions Hospital for a Quality Improvement project on delivery of impacted fetal head at cesarean section. This is a department-wide, simulation-based educational training required for all Regions Hospital Birth Center staff physicians, residents, nursing staff, and surgical techs.
Study NCT00084396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Study NCT01731340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Dietary Calcium
Description: 1200 mg
Study NCT00084396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT03660618 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: laser speckle flowgraphy
Description: blood flow state of the skin as real time two dimensional image
Study NCT00137800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-774 (Tarceva)
Description: Once daily without interruption as long as there is no disease progression or serious side effects experienced.
Study NCT03177512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LYNX Mobile App
Description: Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.
Study NCT02497365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin
Study NCT02497365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin and Cefazolin
Description: Fortified Tobramycin and Cefazolin eye drops
Study NCT04599803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verily Sleep Apnea (VSA) Program/App
Description: The VSA program/app, is an Obstructive Sleep Apnea (OSA) management platform.
Study NCT04094493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vit D
Description: preoperative intra muscular vit D injection
Study NCT03626012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB078
Description: Administered as specified in the treatment arm.
Study NCT03626012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT05052463 — intervention group
Intervention type: OTHER
Intervention: electrolyte imbalance analysis
Description: ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance
Study NCT02173483 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Quadriceps graft
Study NCT03587428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc-A toothpaste
Description: Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-A toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
Study NCT03587428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc-B toothpaste
Description: Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-B toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
Study NCT03587428 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mineral water
Description: Participants received 6.0g (±0.3g) of mineral water (by weighing out), one day per treatment (with at least 2 \[generally 7\] days between treatments). Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
Study NCT00733733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG Fresenius
Description: One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
Study NCT01375816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI 1-Bevacizumab
Study NCT03305913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: TAS-102 tablet
Study NCT03305913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib tablet
Study NCT02933489 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo AB-MR
Study NCT02933489 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis Mammography
Description: Undergo DBT
Study NCT02933489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02933489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02098928 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hand-acupuncture
Description: Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.